AXA Premier VIP Trust Announces a Change of Location of the Special Meeting of Shareholders of the CharterSM Multi-Sector Bond Portfolio, a series of AXA Premier VIP Trust
AXA Premier VIP Trust announces that the Special Meeting of Shareholders of the CharterSM Multi-Sector Bond Portfolio, a series of AXA Premier VIP Trust (the "Trust"), scheduled to be held at the Trust's office, located at 1290 Avenue of the Americas, New York, New York 10104, on April 10, 2020, at 2:30 p.m., Eastern time, will take place remotely, given the rapidly changing situation in New York City related to COVID-19.
The Special Meeting of Shareholders, originally scheduled to be held at the Trust's office, will be conducted on the same date and time, April 10, 2020, at 2:30 p.m., Eastern time, by phone instead of an in-person meeting. For shareholders eligible to give voting instructions, dial-in instructions follow below:
In late February, certain variable annuity and variable life contractholders were sent a notice and proxy statement relating to a Special Meeting of Shareholders of the CharterSM Multi-Sector Bond Portfolio. The purpose of the Special Meeting of Shareholders is to approve an amended Investment Advisory Agreement between the Trust and AXA Equitable Funds Management Group, LLC with respect to the CharterSM Multi-Sector Bond Portfolio.
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...